KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Vir Biotechnology (VIR) EBT (2018 - 2025)

Vir Biotechnology's EBT history spans 8 years, with the latest figure at -$43.1 million for Q4 2025.

  • On a quarterly basis, EBT rose 58.86% to -$43.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$437.8 million, a 16.31% increase, with the full-year FY2025 number at -$437.8 million, up 16.31% from a year prior.
  • EBT hit -$43.1 million in Q4 2025 for Vir Biotechnology, up from -$163.0 million in the prior quarter.
  • Over the last five years, EBT for VIR hit a ceiling of $921.9 million in Q1 2022 and a floor of -$233.7 million in Q2 2022.
  • Historically, EBT has averaged -$14.2 million across 5 years, with a median of -$120.9 million in 2023.
  • The widest YoY moves for EBT: up 646.43% in 2022, down 477.79% in 2022.
  • Tracing VIR's EBT over 5 years: stood at $545.9 million in 2021, then crashed by 127.78% to -$151.6 million in 2022, then rose by 20.36% to -$120.8 million in 2023, then grew by 13.32% to -$104.7 million in 2024, then skyrocketed by 58.86% to -$43.1 million in 2025.
  • Business Quant data shows EBT for VIR at -$43.1 million in Q4 2025, -$163.0 million in Q3 2025, and -$110.8 million in Q2 2025.